The long-term accumulation of β2-microglobulin (β2M) in patients with kidney failure results in a debilitating condition referred to as dialysis-related amyloidosis (DRA). There have been few methods specifically designed to remove the large quantities of β2M that are produced by the body. This article briefly reviews current modalities and concepts for the removal of β2M from blood. The various approaches are classified according to the mechanism of β2M clearance. The potential application of immunoadsorption, a biologically specific approach to remove macromolecules, in the treatment and understanding of DRA is discussed.
ASJC Scopus subject areas